HSD3B1 polymorphisms and hormonal therapy resistance
Menée aux Etats-Unis à partir de données portant sur 443 patients atteints d'un cancer de la prostate résistant à une thérapie anti-androgénique, cette étude rétrospective multi-cohortes évalue l'intérêt d'identifier un polymorphisme du gène HSD3B1(1245C) pour prédire la résistance au traitement et la survie sans progression
Gonadal suppression, achieved by surgical or pharmacological castration, is a mainstay of therapy for recurrent prostate cancer (after definitive local treatment) and metastatic disease. Most men initially respond favourably to gonadal suppression, but virtually all eventually develop biochemical or clinical evidence of disease progression after around 2–10 years in the non-metastatic setting and 1–3 years in the metastatic setting.1 This clinical state, known as castration-resistant prostate cancer, is usually heralded by a shift in androgen signalling from gonadal androgens to adrenal and intratumoral androgens.
The Lancet Oncology , commentaire, 2015